Corporate Governance

Our governance framework and effective management systems, enable us to ensure that management of business risk and regulatory and marketing code compliance are overseen at the highest level of the company.
Kiara Health Governance includes:

Regular internal and external audits to drive good governance, business practices, regulatory and quality assurance performance and continuous improvement.

Senior heads’ responsibilities that encompass setting corporate strategy, managing risk, and ensuring compliance.

(Centre for Infectious Diseases Research & Experimental Therapeutics, Baylor Research Institute, LuminaCare Solutions, Inc., Founder at Jacaranda Biomed Inc.)
Dr Tawanda Gumbo

Tawanda Gumbo is currently the Director of the Centre for Infectious Diseases Research and Experimental Therapeutics (CIDRET), and the Baylor Research Institute, Baylor University Medical Centre, Dallas, Texas, USA; and an Honorary Professor of Medicine, University of Cape Town, Observatory, South Africa. He is the former administrative director of global health research at the University of Texas Southwestern Medical Centre, Dallas, Texas, USA. Dr Gumbo has published seven book chapters, including the introduction to Antibiotics and the Tuberculosis chapter in Goodman and Gillman, considered the “bible” of pharmacology, and the reference book in pharmacology all over the globe. To date he has published more than 110 peer-reviewed scientific articles, virtually all as either first author or senior author.

read more


Scientific achievements, especially in the field of pharmacology and drug development are numerous but include the design of the hollow fibre model of tuberculosis [“glass mouse”] for adult TB 2003.

Within the past year, he led the presentation for the formal qualification approval of the model as a drug development tool by the European Medicines Agency (EMA), the first of its kind: ( and editorial endorsement by the US Food and Drug Administration []. This model has a predictive accuracy of 94% of clinical events, unprecedented in the field of pharmacology. Recently, he has added 3-D human organoids such as the liver to the model, leading to assessment of drug toxicity in the model.

Other scientific achievements include debunking the effectiveness of directly observed therapy in TB, introduction of the role of genetic pharmacokinetic variability as the main cause of therapy failure in TB, and recently overhauling the susceptibility breakpoints. He also pioneered PK/PD of anti-TB drugs and use of pharmaco-metrics in optimizing anti-TB drugs, and wrote the first systems pharmacology equations for interaction of drug and Mycobacterium tuberculosis (2004). He has also introduced the use of artificial intelligence algorithms to the TB field, and before that to infectious diseases while working on the antifungal micafungin. In the past, he designed the mouse model of disseminated Candida glabrata, and performed some of the PK/PD studies during development of all currently licensed echinocandin antifungals. In 2007, he received the NIH Director’s New Innovator Award. He has been the principal investigator for numerous research grants funded by the NIH, Critical Path, Gates, MRC-SA, and pharmaceutical industry grants. He has also been on the drug Safety Monitoring Committee, CROMS Safety Oversight Committee Support, DMID, NIH/NIAID. Dr Gumbo founded Jacaranda Biomed Inc., a company dedicated to helping pharmaceutical companies de-risk lead molecules, improve forecasting early during development for efficacy and toxicity based on innovative tissue platforms, dynamic drug concentrations, next-generation sequencing, and mathematical algorithms. Jacaranda Africa aims to provide a service for rapid evaluation of API for any products being sold on the African continent. He is also a founding partner of Yangu Beauty, a company that has created the first complete skin care line for women of colour (African, Asian, Caribbean, and Middle Eastern) and is the co-founder of Munhu Inc. a 501 (C) 3 in 2004. Munhu Inc. has cared for >20,000 AIDS Orphans in Zimbabwe since its founding. His education includes a Medical Degree (MB, ChB) from the University of Zimbabwe Medical School, Harare, Zimbabwe, Residency in Internal Medicine at Case Western Reserve University, Cleveland, Ohio, and Fellowship, in Infectious Diseases at the Cleveland Clinic, Cleveland, Ohio.


(Founder and Director of iBioMedix Health Systems)
Dr Howard Manyonga

Dr Howard Manyonga is the founder and director of iBioMedix Health Systems, a health systems consultancy. He is an Obstetrician and Gynaecologist who has worked in Sexual and Reproductive Health for more than a fifteen year in the UK and in South Africa. He also has expertise in Clinical Risk Management and was founding faculty for and has been retained by the Medical Protection Society Educational services to run risk management workshops in South Africa, Botswana and Namibia. He has consulted to Provincial Departments of Health and non-governmental organizations in a wide range of areas. His last corporate role was COO of a 14-clinic Sexual and Reproductive Health organization where he had accountability for operational efficiency, quality and financial viability.

read more


He also served as a member of the National Department of Health Technical Working Group on Contraception and Fertility Planning. Dr Manyonga left Marie Stopes to collaborate with PPO Serve, a shared services company adapting the Accountable Care Organization framework to the South African health care market where it is manifest as Integrate Clinical Consortia ™ (ICC). They are now building on the successes of the first such population-based ICC ™ to finalize a novel maternity care product. He also offers advisory services to primary care groups transforming their practices into integrated primary care clinics. He completed the Executive MBA in 2009 at the University of Cape Town Graduate School of Business and was also awarded the Certificate in Work Place Best Practices (Lean Management) by the Japan Association of Overseas Technical Assistance.


(Essential Tech Program at Swiss Federal Institute of Technology, Lausanne| Biotechnology – EPFL, Qwane Biosciences SA)
Dr Soli Makohliso

Dr Makohliso is currently involved at The Essential Tech programme, an EPFL initiative that aims at fostering the development and implementation of essential medical technologies that have the potential to significantly contribute to the achievement of the Sustainable Development Goals. Dr Makohliso is the Co-Founder and Board Member of Qwane Biosciences SA, a spin-out company of Ayanda Biosystems SA focusing on innovative drug discovery and neuroscience research tools for neurodegenerative diseases. Here, he was responsible for responsible for the overall operational management, as well as developing company strategy and business plans; identifying and negotiating the acquisition of new technologies to grow and strengthen the company portfolio; identifying suitable business partnerships and negotiating out-licensing deals. He successfully secured non-dilutive funding of over EUR 5 million for early stage development of company intellectual property and product portfolio. Dr Makohliso was a Research Fellow at École Polytechnique Fédérale de Lausanne (EPFL), where his research focus was on Cell-based biosensor, employing label-free methods such as Surface Plasmon Resonance and Impedance Spectroscopy. He also lectured for the former EPFL Post-Graduate Certificate in Biomedical Engineering (Biomaterials module) for doctors and biologists wishing to work in biomedical engineering field.

(Senior Health Policy Specialist and Consultant)
Dr Roberto Raggi

Dr Roberto Raggi is a senior health policy specialist and is the Principal of a consulting firm (Roberto Raggi and Associates, previously associated with Deloitte group from 1994 to 2010) giving more than 60 major consulting services to Italian, European, US private and public clients on matters such as:

  1. health economics (cost effectiveness analysis, cost studies, etc.),
  2. feasibility studies and business plans for health structures and services,
  3. audit programs for local and regional health authorities,
  4. programming and appraisal of primary healthcare and hospital care, and
  5. strategic development to private healthcare providers and pharmaceutical companies. He has had extensive involvement in technical assistance assignments in public health planning and monitoring and evaluation of the same in about 15 African and Asia countries on contract with the Italian Ministry of Foreign Affairs (Italian Cooperation) and international organizations (World Bank).
(Founder and Executive Chairman of the Board of NEXT)
Dr Giorgio Roscigno

Dr Roscigno is a senior pharma and diagnostics executive with broad managerial and medical experience in the private as well as the public sector. He has contributed significantly, inspired and led the clinical work of all TB fixed-dose combinations containing rifampicin, the development of rifapentine (TB) and DFMO eflornithine (sleeping sickness) up to their FDA approvals. In addition, he has contributed to ground-breaking public health care initiatives among which the global TB alliance (acting-CEO, 2000-2003), the Foundation for Innovative New Diagnostics – FIND (CEO, 2003-2011) and the African Society for Laboratory Medicine – ASLM (COO, 2011-2012).

Dr Roscigno has most recently been a consultant to WHO headquarters in Geneva (Dec 2014 to July 2015) in the preparation and writing of the Strategic Plan for the Ethiopian pharmaceutical sector which is currently being implemented.